Join Team Norway at Nordic Health Summit Japan 2025
24 June 2025 - 27 June 2025
Exhibition
Japan is one of the world's leading healthcare markets and a hub for many of the top global pharma companies, all with a strong interest in Nordic innovation. Nordic Health Summit Japan is a prime opportunity for Norwegian startups and scaleups to explore new avenues of collaboration with key Japanese players in the life sciences and healthcare sectors. The summit is held for the 4th time, and is well-attended by Japanese Big pharma and investors.
Programme elements
Nordic Health Summit is a business development conference to connect Nordic health innovations and Japanese investors and industry
Tuesday June 24th Market Entry Day in Tokyo
Visit a Japanese hospital and a nursing home where a super aging society meeting, cutting age universal healthcare, AI with a personal touch.
Friday June 27th Nordic Health Summit at Takeda Pharmaceuticals Tokyo HQ
Purpose: The Nordic Health Summit Japan is a partnering and investor conference that connects Nordic healthcare innovations and Japanese investors and industry through matchmaking.
Participation: Online or physically in Tokyo.
Secure your place at the networking event for Nordic health innovators and global industry leaders today.
Register for Nordic Health Summit 2025
Deepen Your Market Understanding: Gain valuable insights into the Japanese healthcare market and learn how Nordic healthcare innovation is making a mark.
Access a High-Level Network: Connect with Japanese life science investors and industrial partners looking to collaborate with Nordic startups.
Explore Collaboration and Investment Opportunities: Benefit from curated matchmaking sessions between Norwegian startups and key Japanese investors and companies.
Network with Industry Leaders: Expand your network with potential partners from both the Norwegian and Japanese life sciences and healthcare sectors.
Join us at Nordic Health Summit Japan to position your business at the forefront of this dynamic market, forge strategic partnerships, and drive innovation in collaboration with some of the world’s leading healthcare companies.
Why Japan?
With a population of 125 million, Japan is the third-largest healthcare market globally.
The market is projected to grow steadily, with a CAGR of 4% between 2018 and 2024.
Japan is home to major healthcare giants, including Takeda, Astellas, and Eisai.
As Japan's domestic startup scene is relatively limited, Japanese companies increasingly seek international partners to drive innovation.
Notable examples of Japanese investment in Nordic life science include:
- Eisai's partnership with a Swedish company that led to the world’s first FDA-approved Alzheimer's drug in 2023.
- Fujifilm's $1.6 billion investment to expand advanced manufacturing in Denmark.
Japan offers a comprehensive universal healthcare system, allowing patients freedom in choosing their providers, and healthcare expenditures have surged over 30% since 2000, now making up 11% of GDP.
What to Expect
Nordic Health Summit Japan serves as a key partnering and investment event that brings together Norwegian healthcare innovators with Japanese investors and industry leaders. This is an invaluable opportunity for innovative Norwegian health tech and life sciences companies to connect with Japanese stakeholders, including pharmaceutical companies, investors, and medical device manufacturers eager to collaborate with Nordic partners.
Learn more about the Nordic Health Summit 2025 here.
Important conditions
Companies must adhere to standards for responsible business conduct, including Environmental, Social, and Governance (ESG) criteria.
Participants are expected to operate in accordance with the UN Guiding Principles on Business and Human Rights and the OECD Guidelines for Multinational Enterprises on Responsible Business Conduct. This entails conducting business responsibly, respecting human rights, ensuring decent working conditions, safeguarding environmental considerations, and actively preventing corruption.
Companies must carry out their own due diligence assessments (risk assessments) to identify, prevent, and mitigate potential adverse impacts.